Research programme: antifolates - Chelsea Therapeutics

Drug Profile

Research programme: antifolates - Chelsea Therapeutics

Alternative Names: CH-2308; CH-4446

Latest Information Update: 18 Jan 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of South Alabama
  • Developer Chelsea Therapeutics
  • Class
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Feb 2007 Antifolate compounds are available for licensing worldwide (http://chelseatherapeutics.com/contact.html)
  • 22 Jun 2005 Early research in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top